You are here

The International Journal of Biological Markers
Share

The International Journal of Biological Markers


Editor in Chief
Dr. Massimo Gion Regional Center for Biomarkers, Italy
Co-Editors
Dr. Maria Grazia Daidone National Cancer Institute, Foundation and IRCCS, Italy
Prof. Giampietro Gasparini Cancer Institute IRCCS "Giovanni Paolo II", Italy
Prof. Robin Leake University of Glasgow, United Kingdom
Prof. Masakazu Toi OOTR Institute Kyoto, Japan
Founding Editor
Dr. Emilio Bombardieri Humanitas Gavazzeni, Italy


eISSN: 17246008 | ISSN: 17246008 | Current volume: 33 | Current issue: 1 Frequency: Quarterly

Effective from the 2018 volume International Journal of Biological Markers (IJBM) will be published by SAGE Publishing. Authors should continue to submit as normal. For authors with a paper currently in evaluation and peer review, you will be informed of a decision as normal but any accepted papers will now be published by SAGE.

For more information please click here.

The International Journal of Biological Markers (IJBM) is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers.

IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment. The journal is interested in the publication of studies aimed at validation of biomarkers for clinical application.

In addition, IJBM focuses on research areas that facilitate translational research on biomarkers, such as knowledge translation, bio-banking, biostatistics and method validation and standardization.

The International Journal of Biological Markers (IJBM) is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers.

IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment. The journal is interested in the publication of studies aimed at validation of biomarkers for clinical application.

In addition, IJBM focuses on research areas that facilitate translational research on biomarkers, such as knowledge translation, bio-banking, biostatistics and method validation and standardization.

Subject Area Editor - Gastrointestinal and Pancreatic Cancer
Prof. Nadir Arber Tel Aviv Medical Centre, Israel
Prof. Stefano Cascinu University of Modena, Italy
Dr. Stephan L. Chan Chinese University of Hong Kong, China
Prof. Massimo Falconi Universita Vita e Salute San Raffaele Ospedale San Raffaele IRCCS, Italy
Subject Area Editor - Clinical Laboratory
Prof. Vivian Barak Hadassah Medical Center, Israel
Dr. Mario Correale IRCCS DE BELLIS, Italy
Dr. Ruggero Dittadi Ospedale dell'Angelo, Italy
Dr. Rafael Molina Biomedical Diagnostic Center, Spain
Prof. Mario Plebani University of Padua, Italy
Subject Area Editor - Gynecological Cancer
Dr. Robert C. Bast, Jr MD Anderson Cancer Centre, United States
Prof. Tiziano Maggino Ospedale dell'angelo Mestre, Italy
Prof. Paolo Zola Città della Salute e della Scienza" University Hospital, Italy
Subject Area Editor - Urological Cancer
Prof. Francesco Boccardo University of Genoa, Italy
Dr. Valentina Casadio Istituto scientifico Romagnolo per lo Studio e la Cura dei tumori (IRST) IRCCS, Italy
Prof. Antonio Lopez-Beltran University of Cordoba, Spain
Prof. Rodolfo Montironi Polytechnic University of the Marche Region, Italy
Prof. Axel Semjonow University Hospital Münster, Germany
Subject Area Editor - Statistics and Research Methodology
Prof. Patrizia Boracchi University of Milan, Italy
Dr. Luigi Mariani Fondazione IRCCS Istituto Nazionale Tumori, Italy
Dr. Valter Torri Mario Negri Institute IRCCS, Italy
Subject Area Editor - Clinical and Molecular Epidemiology
Dr. Paolo Bruzzi National Cancer Research Institute, Italy
Prof. Paola Muti McMaster University, Canada
Dr. Marco Zappa Institute for Study and Prevention of Cancer (ISPO), Italy
Subject Area Editor - Prognostic/Predictive Markers
Prof. Jennifer Byrne Kids Research Institute (KRI), Australia
Prof. Xichun Hu Fudan University Shanghai Cancer Center, China
Prof. Rosella Silvestrini National Cancer Institute, Foundation and IRCCS, Italy
Subject Area Editor - Pathology
Dr. Antonino Carbone IRCCS CRO Aviano and A.O., Italy
Prof. Paola Cassoni University of Turin, Italy
Prof. Hironobu Sasano Tohoku University Hospital, Japan
Subject Area Editor - Targeted Therapies
Prof. Louis WC Chow Organisation for Oncology and Translational Research, China
Dr. Stefan Glück University of Miami, United States
Subject Area Editor - Basic and Preclinical Research
Dr. Elda Tagliabue National Cancer Institute, Foundation and IRCCS, Italy
Prof. Michele De Bortoli University of Turin, Italy
Subject Area Editor - Melanoma and Sarcoma
Prof. Carlo Riccardo Rossi University of Padua, Italy
Subject Area Editor - Mesothelioma
Dr. Marcello Deraco Fondazione IRCCS Istituto Nazionale Tumori, Italy
Subject Area Editor - Lung Cancer
Prof. Massimo Di Maio University of Turin, Italy
Prof. Maria Planck Lund University, Sweden
Prof. Giorgio Vittorio Scagliotti University of Turin, Italy
Prof. Yi-long Wu Guangdong General Hospital, China
Subject Area Editor - Microenvironment & Immunology
Dr. Aline S.C. Fabricio Regional Centre for Biomarkers, Italy
Dr. Valter Gattei CRO-National Cancer Institute, Italy
Prof. Douglas Noonan University of Insubria, Italy
Subject Area Editor - Neuro-Oncology
Prof. Manuel Graeber University of Sydney Brain and Mind Centre, Australia
Subject Area Editor - Biospecimens & Biorepositories
Dr. Fiorella Guadagni IRCCS San Raffaele Pisana, Italy
Subject Area Editor - Hepatobiliary Tract Cancer
Dr. Etsuro Hatano Kyoto University, Japan
Prof. Patrizia Pontisso University of Padua, Italy
Subject Area Editor - Breast Cancer
Prof. Chiun-Sheng Huang National Taiwan University Hospital, China
Dr. Giorgio Secreto National Cancer Institute, Foundation and IRCCS, Italy
Prof. Binghe Xu Chinese Academy of Medical Sciences, China
Subject Area Editor - Biomarkers and Imaging Integration
Prof. Giuseppe Madeddu University of Sassari, Italy
Dr. Domenico Rubello Santa Maria della Misericordia Hospital, Italy
Prof. Marco Salvatore University of Naples Federico II, Italy
Subject Area Editor - Head and Neck Cancer
Prof. Gino Marioni University of Padua, Italy
Subject Area Editor - Biomarker Discovery (-omics)
Dr. Pierluigi Mauri Institute for Biomedicl Technologies (ITB-CNR), Italy
Dr. Maria Pasic St. Joseph's Health Centre, Canada
Subject Area Editor - Liquid Biopsies
Prof. Kevin Spring Western Sydney University, Australia
Subject Area Editor - Knowledge Translation and Appropriateness
Dr. Parvin Tajik University of Amsterdam, Netherlands
Dr. Chiara Trevisiol Veneto Institute of Oncology IOV-IRCCS, Italy
Subject Area Editor - Molecular Diagnostics and Pharmacogenomics
Dr. Giuseppe Toffoli CRO-National Cancer Institute, Italy
Prof. Theoni Trangas University of Ioannina, Greece
  • CNKI Scholar
  • Clarivate Analytics: BIOSIS Previews
  • Clarivate Analytics: Biological Abstracts
  • Clarivate Analytics: Current Contents - Clinical Medicine
  • Clarivate Analytics: Current Contents - Life Sciences
  • Clarivate Analytics: Science Citation Index Expanded
  • EBSCO Discovery Service
  • Embase
  • J-Gate
  • Journal Citation Reports/Science Edition
  • Ovid
  • PubMed: MEDLINE
  • Scopus
  • Manuscript Submission Guidelines: The International Journal of Biological Markers

    This Journal is a member of the Committee on Publication Ethics

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the Journal’s submission site www.editorialmanager.com/jbm to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of The International Journal of Biological Markers will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to Dr. Antonette Leon at The International Journal of Biological Markers editorial office as follows: journal.biomarkers@aulss3.veneto.it

    1. What do we publish?
      1.1 Aims & Scope
      1.2 Article types
      1.3 Writing your paper
    2. Editorial policies
      2.1 Peer review policy
      2.2 Authorship
      2.3 Acknowledgements
      2.4 Funding
      2.5 Declaration of conflicting interests
      2.6 Research ethics and patient consent
      2.7 Clinical trials
      2.8 Reporting guidelines
    3. Publishing policies
      3.1 Publication ethics
      3.2 Contributor's publishing agreement
      3.3 Publication charges
      3.4 Open access and author archiving
    4. Preparing your manuscript
      4.1 Formatting
      4.2 Artwork, figures and other graphics
      4.3 Supplementary material
      4.4 Reference style
      4.5 English language editing services
    5. Submitting your manuscript
      5.1 ORCID
      5.2 Information required for completing your submission
      5.3 Permissions
    6. On acceptance and publication
      6.1 SAGE Production
      6.2 Online First publication
      6.3 Access to your published article
      6.4 Promoting your article
    7. Further information

     

    1. What do we publish?

    1.1 Aims & Scope

    Before submitting your manuscript to The International Journal of Biological Markers, please ensure you have read the Aims & Scope.

    1.2 Article Types

    Original research articles

    Previously unpublished manuscripts, describing clinical, pre-clinical, epidemiological investigations, clinical trials, clinical observations, and other relevant investigations that are based on sound patient series, validated analytical methods, and appropriate statistical evaluation.

    Original research articles should be structured as follows: Introduction (clearly stating an objective or hypothesis), Methods (describing the study design and methods applied, including the study setting and dates, patients or participants with inclusion and exclusion criteria, and/or participation or response rates, or data sources, and how these were selected for the study), Results (describing the results of the study in context with the published literature and addressing study limitations), and Discussion (addressing relevant implications for clinical practice or health policy). A structured abstract is required.

    Words: max 3000 (excluding figures and tables)
    Figures/Tables: max 5
    References: max 50

    Clinical trial protocols

    A clinical trial is defined as any research project that prospectively assigns human participants to intervention or comparison groups to study the cause-and-effect relationship between an intervention and a health outcome. Each manuscript should be divided as follows: Introduction (stating an objective or hypothesis of the protocols), Methods (describing the design and statistical methods applied, including the study setting and dates, patients or participants with inclusion and exclusion criteria), Results (including data on recruitment, etc.), and Discussion (placing the protocol in context with the published literature). A structured abstract is required, and trial registration information (name, number, and URL) must be listed in the title page.

    Words: max 3000 (excluding figures and tables)
    Figures/Tables: max 6
    References: max 50

    Reviews

    Reviews are solicited by the Editor in Chief on topics that are deemed to be relevant to the audience of the Journal. Containing the current state of knowledge or practice, integrating recent advances with accepted principles and practice, or summarizing and analyzing consensus view of controversial issues in knowledge of practice. A non-structured abstract is required.

    Words: max 5000 (excluding figures and tables)
    Figures/Tables: max 5
    References: no limit

    Editorials

    The purpose of the editorials is to provide the reader with a balanced overview of relevant and up to date subjects concerning the Journal's aim or future direction. A non-structured abstract is not required.

    Words: max 1500 (excluding figures and tables)
    Figures/Tables: max 2
    References: max 15

    Technical briefs

    Technical briefs are papers on methodological comparisons, new method development or other methodological approaches. They should have a short Introduction, Methods, Results and a brief Conclusion.

    Words: max 3000 (excluding figures and tables)
    Figures/Tables: max 5
    References: max 20

    Short communications

    This article type reports of results from original researches. They must provide conclusive findings: preliminary observations or incomplete findings cannot be considered for publication. A non-structured abstract is required.

    Words: max 2000 (excluding figures and tables)
    Figures/Tables: max 3
    References: max 20

    Case reports

    Case reports will be accepted if they describe a previously undescribed clinical case and are of very high importance for dissemination. Case reports must be structured as follows: Introduction (explaining the importance of the case), Case Description (providing all relevant information), and Conclusions (describing the detailed outcome of the report). A structured abstract is required.

    Words: max 2000 (excluding figures and tables)
    Figures/Tables: max 3
    References: max 10

    Correspondence

    Letters to the Editor are intended to present opinions or comments on articles published in the Journal. Letters are subject to abridgement and editing for style and content. An abstract is not required.

    If you are the corresponding author of an article cited in a Letter to the Editor and receive an email invitation to comment on it, you must log in to the system, accept the invitation immediately, and then upload and submit your reply to the Editorial Office. The response must cite the title of the letter, e.g., “Response to (Title of Letter)”.

    Words: max 750 (excluding figures and tables)
    Figures/Tables: 1
    References: max 5

    1.3 Writing your paper

    The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.

    1.3.1 Make your article discoverable

    When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online

    Back to top

    2. Editorial policies

    2.1 Peer review policy

    Manuscripts that do not adhere to the guidelines for submission will be returned to the corresponding author for technical revision before undergoing the peer review process. Manuscripts with insufficient priority for publication will be rejected promptly.

    Peer review is the process we use to assess the quality of a manuscript to see if it suitable for publication. Independent researchers with similar competencies assess submitted manuscripts for originality, validity and importance to help our Editors determine if a manuscript is suitable for publication in their journal.

    We utilise a single-blind peer-review system, which is considered to be self-regulating. Reviewers are aware of the names and affiliations of the authors, but the reviewer assessments provided to authors are completely anonymous. The single-blind peer review system is the most commonly-used method of review and most Reviewers are comfortable with this approach, as it facilitates an impartial appraisal of a manuscript.

    Submitted manuscripts are reviewed by two or more referees who evaluate whether the manuscript is scientifically logical and well-constructed, focussing specifically on if it duplicates previously published work, and if there are clear grounds for it to be considered for publication. The Editors establish their decision based on these reports and, if necessary, they can discuss with members of the Editorial Board.

    We aim to provide authors with a first decision (of accept, reject or revisions required whether minor or major) within 4 weeks.

    All correspondence related to the submission, including editorial decisions, will be sent by email to the corresponding author. In case of revision, detailed revision instructions will be sent and a point-by-point response will be required. The Journal does not reveal the identity of its reviewers.

    Authors can check the status of their manuscript at any time by logging into the journal's submission system, Editorial Manager.

    Appeals and complaints
    If you would like to appeal a rejection decision or make a complaint, please contact the Publisher who will outline the journal's complaints procedure.

    As part of the submission process you will be asked to provide the names of a minimum of 2 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:

    • The reviewer should have no prior knowledge of your submission
    • The reviewer should not have recently collaborated with any of the authors
    • Reviewer nominees from the same institution as any of the authors are not permitted

    You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers).

    Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

    2.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    • Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
    • Drafted the article or revised it critically for important intellectual content,
    • Approved the version to be published,
    • Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

     2.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

    2.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    2.4 Funding

    The International Journal of Biological Markers requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. 

    2.5 Declaration of conflicting interests

    It is the policy of The International Journal of Biological Markers to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here

    2.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. . Experimental research performed on animals must comply with the NIH Guide for the Care and Use of Laboratory Animals or equivalent. A statement that research has been performed according to the NIH Guidelines must be included in the Methods section.

    2.7 Clinical trials

    The International Journal of Biological Markers endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.

    2.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives

     

    Back to top

    3. Publishing Policies

    3.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway

    3.1.1 Plagiarism

    The International Journal of Biological Markers and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    3.1.2 Prior publication

    If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    3.2 Contributor's publishing agreement

    Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway.

    3.3 Publication charges

    There is no charge for publishing in The International Journal of Biological Markers for articles or other contributions equal to or less than 4,000 words. For any contribution over 4,000 words a publication charge of £300 (£210 for members of affiliated societies) (plus VAT where applicable) to support the costs of dissemination will apply. The 4,000 word limit includes the title, abstract, keywords, main article, tables, declarations, any acknowledgments or notes, and references. 

    SAGE may choose to publish selected articles prior to payment; however publication of the accepted article does not constitute waiving of the charge. SAGE reserves the right to refuse future submissions if there are outstanding payments due.

    An invoice will be sent to your nominated billing address. Payment terms are 30 days from the invoice date. If you would like to pay by credit card please contact us at credit.control@sagepub.co.uk for further information.

    3.4 Open access and author archiving

    The International Journal of Biological Markers offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.

    Back to top

    4. Preparing your manuscript for submission

    4.1 Formatting

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    4.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines  

    Figures supplied in colour will appear in colour online regardless of whether or not these illustrations are reproduced in colour in the printed version. For specifically requested colour reproduction in print, you will receive information regarding the costs from SAGE after receipt of your accepted article.

    4.3 Supplementary material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files

    4.4 Reference style

    The International Journal of Biological Markers adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.

     If you use EndNote to manage references, you can download the SAGE Vancouver EndNote output file

    4.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

    Back to top

    5. Submitting your manuscript

    The International Journal of Biological Markers is hosted on Editorial Manager, a web based online submission and peer review system. Visit www.editorialmanager.com/jbm to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. 

    5.1 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.

    It is mandatory for all authors to add their ORCIDs to their Editorial Manager accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here

    5.2 Information required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    5.3 Permissions

    Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway

    Back to top

    6. On acceptance and publication

    6.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

    6.2 Online First publication

    Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.

    6.3 Access to your published article

    SAGE provides authors with online access to their final article.

    6.4 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos

    Back to top

    7. Further information

    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to The International Journal of Biological Markers editorial office as follows: journal.biomarkers@aulss3.veneto.it

    Individual Subscription, E-access


    Institutional Subscription, E-access